Curative Historical Balance Sheet

CUBT Stock

USD 0.01 0.0004 2.99%

Trend analysis of Curative Biotechnology balance sheet accounts such as Other Liab of 523.9 K, Accounts Payable of 4.2 M or Net Receivables of 109.3 K provides information on Curative Biotechnology's total assets, liabilities, and equity, which is the actual value of Curative Biotechnology to its prevalent stockholders. By breaking down trends over time using Curative Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Curative Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Curative Biotechnology is a good buy for the upcoming year.

Curative Biotechnology Inventory

(98,859.37)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.

About Curative Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Curative Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Curative Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Curative Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Curative currently owns. An asset can also be divided into two categories, current and non-current.

Curative Biotechnology Balance Sheet Chart

At this time, Curative Biotechnology's Non Current Assets Total are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.1 M in 2025, despite the fact that Retained Earnings are likely to grow to (32.7 M).

Total Current Liabilities Other Liab Accounts Payable Common Stock

Total Current Liabilities

Total Current Liabilities is an item on Curative Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Curative Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Curative Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Curative Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Curative Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Curative Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.At this time, Curative Biotechnology's Non Current Assets Total are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.1 M in 2025, despite the fact that Retained Earnings are likely to grow to (32.7 M).

	2024	2025 (projected)
Other Liabilities	649.7K	523.9K
Total Current Liabilities	6.6M	6.9M

Other Liab Total Current Liabilities

Curative Biotechnology balance sheet Correlations

	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Inventory	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Term Debt	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock	Good Will
Total Current Liabilities		0.34	-0.81	-0.9	0.99	0.5	-0.72	0.17	-0.56	-0.18	0.82	0.95	-0.75	-0.28	0.58	0.95	0.92	0.85	0.92	0.45	0.95	-0.86	0.86	-0.9	-0.68	-0.02
Other Liab	0.34		-0.33	-0.35	0.32	-0.34	-0.39	0.2	-0.63	-0.35	0.37	0.32	-0.32	-0.21	0.16	0.25	0.33	0.4	0.35	0.26	0.32	-0.35	0.38	-0.22	-0.36	0.14
Net Tangible Assets	-0.81	-0.33		0.98	-0.78	-0.46	0.91	-0.34	0.62	0.16	-0.92	-0.86	0.52	0.7	-0.78	-0.62	-0.97	-0.89	-0.96	-0.82	-0.86	0.99	-0.95	0.71	0.89	-0.5
Retained Earnings	-0.9	-0.35	0.98		-0.88	-0.49	0.88	-0.28	0.62	0.18	-0.91	-0.92	0.61	0.59	-0.76	-0.75	-0.99	-0.93	-0.98	-0.72	-0.92	0.99	-0.96	0.81	0.85	-0.35
Accounts Payable	0.99	0.32	-0.78	-0.88		0.52	-0.67	0.07	-0.52	-0.16	0.77	0.91	-0.77	-0.31	0.58	0.93	0.9	0.83	0.89	0.46	0.91	-0.84	0.83	-0.94	-0.62	-0.09
Net Receivables	0.5	-0.34	-0.46	-0.49	0.52		-0.37	0.19	0.25	0.46	0.45	0.51	-0.4	-0.17	0.42	0.57	0.48	0.46	0.48	0.26	0.51	-0.46	0.39	-0.55	-0.38	-0.17
Inventory	-0.72	-0.39	0.91	0.88	-0.67	-0.37		-0.66	0.75	0.3	-0.97	-0.78	0.6	0.67	-0.51	-0.56	-0.85	-0.77	-0.87	-0.8	-0.78	0.9	-0.9	0.5	0.99	-0.46
Total Current Assets	0.17	0.2	-0.34	-0.28	0.07	0.19	-0.66		-0.43	-0.19	0.61	0.32	-0.32	-0.21	-0.1	0.17	0.23	0.24	0.32	0.3	0.32	-0.3	0.37	0.19	-0.71	0.29
Common Stock	-0.56	-0.63	0.62	0.62	-0.52	0.25	0.75	-0.43		0.67	-0.69	-0.55	0.51	0.48	-0.22	-0.38	-0.6	-0.54	-0.62	-0.57	-0.55	0.64	-0.69	0.32	0.71	-0.34
Property Plant Equipment	-0.18	-0.35	0.16	0.18	-0.16	0.46	0.3	-0.19	0.67		-0.23	-0.13	0.24	0.17	0.06	-0.08	-0.16	-0.18	-0.17	-0.19	-0.13	0.19	-0.23	0.04	0.26	-0.11
Total Assets	0.82	0.37	-0.92	-0.91	0.77	0.45	-0.97	0.61	-0.69	-0.23		0.9	-0.62	-0.54	0.54	0.7	0.91	0.81	0.94	0.7	0.9	-0.92	0.94	-0.58	-0.97	0.4
Short Long Term Debt Total	0.95	0.32	-0.86	-0.92	0.91	0.51	-0.78	0.32	-0.55	-0.13	0.9		-0.63	-0.27	0.62	0.9	0.94	0.86	0.96	0.46	1.0	-0.88	0.9	-0.78	-0.77	0.19
Other Current Liab	-0.75	-0.32	0.52	0.61	-0.77	-0.4	0.6	-0.32	0.51	0.24	-0.62	-0.63		0.17	-0.08	-0.75	-0.59	-0.58	-0.61	-0.3	-0.63	0.57	-0.67	0.63	0.55	0.3
Total Stockholder Equity	-0.28	-0.21	0.7	0.59	-0.31	-0.17	0.67	-0.21	0.48	0.17	-0.54	-0.27	0.17		-0.58	0.0	-0.57	-0.47	-0.52	-0.98	-0.27	0.67	-0.59	0.3	0.66	-0.62
Property Plant And Equipment Net	0.58	0.16	-0.78	-0.76	0.58	0.42	-0.51	-0.1	-0.22	0.06	0.54	0.62	-0.08	-0.58		0.4	0.76	0.79	0.71	0.63	0.62	-0.76	0.63	-0.67	-0.49	0.48
Net Debt	0.95	0.25	-0.62	-0.75	0.93	0.57	-0.56	0.17	-0.38	-0.08	0.7	0.9	-0.75	0.0	0.4		0.76	0.73	0.79	0.18	0.9	-0.68	0.7	-0.84	-0.53	-0.26
Non Current Assets Total	0.92	0.33	-0.97	-0.99	0.9	0.48	-0.85	0.23	-0.6	-0.16	0.91	0.94	-0.59	-0.57	0.76	0.76		0.9	0.99	0.72	0.94	-0.98	0.96	-0.82	-0.82	0.35
Common Stock Shares Outstanding	0.85	0.4	-0.89	-0.93	0.83	0.46	-0.77	0.24	-0.54	-0.18	0.81	0.86	-0.58	-0.47	0.79	0.73	0.9		0.89	0.59	0.86	-0.91	0.86	-0.8	-0.73	0.26
Other Stockholder Equity	0.92	0.35	-0.96	-0.98	0.89	0.48	-0.87	0.32	-0.62	-0.17	0.94	0.96	-0.61	-0.52	0.71	0.79	0.99	0.89		0.68	0.96	-0.97	0.97	-0.78	-0.86	0.36
Total Liab	0.45	0.26	-0.82	-0.72	0.46	0.26	-0.8	0.3	-0.57	-0.19	0.7	0.46	-0.3	-0.98	0.63	0.18	0.72	0.59	0.68		0.46	-0.8	0.74	-0.4	-0.79	0.62
Short Term Debt	0.95	0.32	-0.86	-0.92	0.91	0.51	-0.78	0.32	-0.55	-0.13	0.9	1.0	-0.63	-0.27	0.62	0.9	0.94	0.86	0.96	0.46		-0.88	0.9	-0.78	-0.77	0.19
Net Invested Capital	-0.86	-0.35	0.99	0.99	-0.84	-0.46	0.9	-0.3	0.64	0.19	-0.92	-0.88	0.57	0.67	-0.76	-0.68	-0.98	-0.91	-0.97	-0.8	-0.88		-0.96	0.77	0.87	-0.42
Short Long Term Debt	0.86	0.38	-0.95	-0.96	0.83	0.39	-0.9	0.37	-0.69	-0.23	0.94	0.9	-0.67	-0.59	0.63	0.7	0.96	0.86	0.97	0.74	0.9	-0.96		-0.69	-0.89	0.42
Net Working Capital	-0.9	-0.22	0.71	0.81	-0.94	-0.55	0.5	0.19	0.32	0.04	-0.58	-0.78	0.63	0.3	-0.67	-0.84	-0.82	-0.8	-0.78	-0.4	-0.78	0.77	-0.69		0.43	0.14
Capital Stock	-0.68	-0.36	0.89	0.85	-0.62	-0.38	0.99	-0.71	0.71	0.26	-0.97	-0.77	0.55	0.66	-0.49	-0.53	-0.82	-0.73	-0.86	-0.79	-0.77	0.87	-0.89	0.43		-0.5
Good Will	-0.02	0.14	-0.5	-0.35	-0.09	-0.17	-0.46	0.29	-0.34	-0.11	0.4	0.19	0.3	-0.62	0.48	-0.26	0.35	0.26	0.36	0.62	0.19	-0.42	0.42	0.14	-0.5

Click cells to compare fundamentals

Curative Biotechnology Account Relationship Matchups

Curative Biotechnology balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	665.0K	730.3K	4.5M	5.7M	6.6M	6.9M
Retained Earnings	(8.1M)	(26.9M)	(32.6M)	(38.2M)	(34.4M)	(32.7M)
Accounts Payable	97.83	726.9	3.4M	3.5M	4.0M	4.2M
Total Current Assets	2.1M	753.9K	68.7K	604.5K	695.1K	369.0K
Common Stock	83.0	143.0	57.9K	90.3K	81.3K	77.2K
Total Assets	2.3M	2.4M	2.1M	2.6M	3.0M	3.1M
Short Long Term Debt Total	124.8	559.8K	1.1M	2.3M	2.6M	2.7M
Other Current Liab	535.6K	(124.8)	105.1K	729.6K	(17.2K)	0.0
Total Stockholder Equity	(4.5M)	(16.4M)	(20.5M)	(3.1M)	(2.8M)	(3.0M)
Property Plant And Equipment Net	2.3K	6.7K	6.3K	5.8K	6.7K	4.9K
Net Debt	399.2K	(670.3K)	1.0M	2.2M	2.5M	2.7M
Non Current Assets Total	142.6K	1.7M	2.0M	2.0M	2.3M	2.4M
Common Stock Shares Outstanding	326.7M	501.0M	572.0M	662.2M	761.5M	461.0M
Liabilities And Stockholders Equity	2.3M	2.4M	2.1M	2.6M	3.0M	3.1M
Other Stockholder Equity	9.7M	28.6M	30.0M	35.0M	40.2M	42.3M
Total Liab	6.8M	18.8M	22.6M	5.7M	6.6M	7.8M
Short Term Debt	124.8	559.8K	1.1M	2.3M	2.6M	2.7M
Cash	160.6K	670.3K	58.7K	56.4K	64.9K	61.6K
Net Invested Capital	(360.8K)	(4.0M)	(16.4M)	(19.5M)	(17.5M)	(16.6M)
Net Working Capital	(397.1K)	1.5M	23.6K	(4.4M)	(4.0M)	(3.8M)
Intangible Assets	140.3	1.6K	1.5M	1.4M	1.6M	1.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Curative Historical Balance Sheet

Curative Biotechnology Inventory

(98,859.37)

About Curative Balance Sheet Analysis

Curative Biotechnology Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Curative Biotechnology balance sheet Correlations

Curative Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Curative Biotechnology balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Curative Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Accounts Payable	+ 0.99	Total Current Liabilities
Net Invested Capital	+ 0.99	Net Tangible Assets
Net Invested Capital	+ 0.99	Retained Earnings
Capital Stock	+ 0.99	Inventory
Other Stockholder Equity	+ 0.99	Non Current Assets Total

Non Current Assets Total	- 0.99	Retained Earnings
Net Invested Capital	- 0.98	Non Current Assets Total
Total Liab	- 0.98	Total Stockholder Equity
Other Stockholder Equity	- 0.98	Retained Earnings
Net Invested Capital	- 0.97	Other Stockholder Equity
Capital Stock	- 0.97	Total Assets